Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy

Research output: Contribution to journalArticle


  • Adam S. Helms
  • Vi T. Tang
  • Thomas S. O’Leary
  • Sabrina Friedline
  • Mick Wauchope
  • Akul Arora
  • Aaron H. Wasserman
  • Eric D. Smith
  • Lap Man Lee
  • Xiaoquan W. Wen
  • Jordan A. Shavit
  • Allen P. Liu
  • Michael J. Previs
  • Sharlene M. Day

External Institution(s)

  • University of Michigan, Ann Arbor
  • University of Vermont


Original languageEnglish (US)
Article numbere133782
JournalJCI Insight
Issue number2
StatusPublished - Jan 30 2020


Mutations in cardiac myosin binding protein C (MyBP-C, encoded by MYBPC3) are the most common cause of hypertrophic cardiomyopathy (HCM). Most MYBPC3 mutations result in premature termination codons (PTCs) that cause RNA degradation and a reduction of MyBP-C in HCM patient hearts. However, a reduction in MyBP-C has not been consistently observed in MYBPC3-mutant induced pluripotent stem cell cardiomyocytes (iPSCMs). To determine early MYBPC3 mutation effects, we used patient and genome-engineered iPSCMs. iPSCMs with frameshift mutations were compared with iPSCMs with MYBPC3 promoter and translational start site deletions, revealing that allelic loss of function is the primary inciting consequence of mutations causing PTCs. Despite a reduction in wild-type mRNA in all heterozygous iPSCMs, no reduction in MyBP-C protein was observed, indicating protein-level compensation through what we believe is a previously uncharacterized mechanism. Although homozygous mutant iPSCMs exhibited contractile dysregulation, heterozygous mutant iPSCMs had normal contractile function in the context of compensated MyBP-C levels. Agnostic RNA-Seq analysis revealed differential expression in genes involved in protein folding as the only dysregulated gene set. To determine how MYBPC3-mutant iPSCMs achieve compensated MyBP-C levels, sarcomeric protein synthesis and degradation were measured with stable isotope labeling. Heterozygous mutant iPSCMs showed reduced MyBP-C synthesis rates but a slower rate of MyBP-C degradation. These findings indicate that cardiomyocytes have an innate capacity to attain normal MyBP-C stoichiometry despite MYBPC3 allelic loss of function due to truncating mutations. Modulating MyBP-C degradation to maintain MyBP-C protein levels may be a novel treatment approach upstream of contractile dysfunction for HCM.

Citation formats


Helms, A. S., Tang, V. T., O’Leary, T. S., Friedline, S., Wauchope, M., Arora, A., ... Day, S. M. (2020). Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy. JCI Insight, 5(2), [e133782]. https://doi.org/10.1172/jci.insight.133782


Helms, AS, Tang, VT, O’Leary, TS, Friedline, S, Wauchope, M, Arora, A, Wasserman, AH, Smith, ED, Lee, LM, Wen, XW, Shavit, JA, Liu, AP, Previs, MJ & Day, SM 2020, 'Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy', JCI Insight, vol. 5, no. 2, e133782. https://doi.org/10.1172/jci.insight.133782